Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Glaxo

This article was originally published in The Tan Sheet

Executive Summary

Glaxo: Supplementary NDA for use of Flonase nasal spray in children ages 4-11 for treatment of seasonal and perennial allergic rhinitis filed Oct. 31, the company announces Dec. 5. Flonase (fluticasone propionate), an Rx product that is a potential candidate for OTC switch, is a once-a-day spray indicated for treatment of seasonal and perennial nasal allergies in patients 12 and older, the company says, adding that the product is not yet indicated for treatment of allergic rhinitis...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts